Monoclonal Antibody Improved Clinical Symptoms, Quality of Life Among Patients With Atopic Dermatitis

In a systematic review and meta-analysis, researchers assessed the safety and efficacy of dupilumab on atopic dermatitis (AD) clinical symptoms, quality of life, and adverse events.

A total of 14 placebo-controlled randomized trials were included in the analysis, 12 comprised adults (n=3817) and 2 comprised children/adolescents (n=618).

From the results, human monoclonal antibody and IL-4/IL-13 blocker dupilumab decreased the Eczema Area Severity Index (EASI) score [standardized mean difference (SMD) = -0.98; 95% confidence interval (95% CI)=(-1.09, -0.88)].

Data also demonstrated dupilumab decreased the percentage different in the Scoring Atopic Dermatitis [mean difference (MD) = -31.56, 95% CI = (-33.75, -29.36)], and in pruritus Numeric Rating Scale [MD = -29.24, 95% CI = (-32.11, -26.37)].

“It also achieved a reduction of at least ≥75% in the EASI score [RR=2.89, 95% CI = (2.47, 3.38)],” explained authors, “[as well as] the Investigator’s Global Assessment (IGA) score ≤1 [RR = 3.47, 95% CI = (2.96, 4.06)].”

Compared to placebo, dupilumab was not associated with any signs of increased adverse events.

“Dupilumab improved clinical symptoms and quality of life in adults and children/adolescents with a safety profile comparable to placebo,” concluded researchers. 

Reference:
Koskeridis F, Evangelou E, Ntzani EE, Kostikas K, Tsabouri S. Treatment with dupilumab in patients with atopic dermatitis: systematic review and meta-analysis. Published online October 9, 2022. J Cutan Med Surg. doi:10.1177/12034754221130969